Most recent articles by:

Editorial Team

- Advertisement -

Phase 2/3 of Athira Trial for Alzheimer’s Fails

Athira Pharma’s Phase 2/3 Alzheimer’s disease trial has ended in failure. The trial revealed that fosgonimeton performed no better than a placebo for the...

Sanofi’s Tolebrutinib faces defeat in 2 out of 3 phase 3 MS trials

Sanofi has announced that tolebrutinib, a BTK inhibitor, failed in two out of three Phase 3 trials. Tolebrutinib was being evaluated across two forms...

Illumina Gets Favorable Decision Regarding Grail Acquisition

In a decision expected to limit Brussels' merger authority, American gene sequencing firm Illumina prevailed in court against the European Union's inquiry into its...

Onward awarded $1.1M grant from the Christopher & Dana Reeve Foundation to advance BCI research

Onward Medical revealed that it has received a major grant from the Christopher & Dana Reeve Foundation to continue with BCI research. This $1.1M...

Life Sciences Voice Top Five Newsletter

Welcome to the latest edition of the Life Sciences Voice Top Five Newsletter, your source for the latest news in the life sciences industry!...

Emergent Bio’s Smallpox Vaccine Gains FDA Approval for Mpox

Emergent BioSolutions' smallpox vaccine has received expanded approval from the U.S. Food and Drug Administration (FDA) for use in individuals at high risk of...

Allist Secures Leading Role in China’s KRAS Inhibitor Market with $21M Jacobio Deal

Shanghai Allist Pharmaceuticals has significantly bolstered its position in China's burgeoning KRAS inhibitor market through a strategic agreement with Jacobio Pharma. This deal, valued...

Siemens Healthineers to Acquire Novartis’ European Radiodiagnostic Production Network

As part of its strategy to expand PET imaging capabilities, Siemens Healthineers will acquire the radiodiagnostic production and distribution platforms affiliated with Novartis’ Advanced...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm
- Advertisement -